Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

• DOI: 10.1016/j.mcpro.2023.100625
• Publication Date: 2023-07-26T03:02:24Z
• Authors: Ning Lou; Guibin Wang; Yanrong Wang; Meng Xu; Yu Zhou; Qiaoyun Tan; Qiaofeng Zhong; Lei Zhang; Xiaomei Zhang; Shuxia Liu; Rongrong Luo; Shasha Wang; Le Tang; Jiarui Yao; Zhishang Zhang; Yuankai Shi; Xiaobo Yu; Xiaohong Han
• Keywords: International Prognostic Index; Proteome; Biomarker Discovery

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, although disease stratification using in-depth plasma proteomics has not been performed to date. By measuring more than 1000 proteins in the of 147 DLBCL patients data-independent acquisition mass spectrometry and antibody array, were classified into four proteomic subtypes (PS-I-IV). Patients with PS-IV subtype worst prognosis had increased levels involved inflammation, including high expression metalloproteinase inhibitor-1 (TIMP-1) that was associated poor survival across two validation cohorts (n = 180). Notably, combination TIMP-1 international prognostic index (IPI) identified 64.00% 88.24% relapsed 65.00% 80.49% deceased discovery cohorts, which represents 24.00% 41.67% 20.00% 31.70% improvement compared IPI score alone, respectively. Taken together, we demonstrate heterogeneity reflected proteome TIMP-1, together IPI, could improve patients.